Evidence map›Paper›PMID 31758081›Full record

ArticleScientific reports2019

Author Correction: Modeling ErbB2-p130Cas interaction to design new potential anticancer agents.

Andrea Costamagna, Matteo Rossi Sebastiano, Dora Natalini, Matilde Simoni, Giorgio Valabrega, Paola Defilippi, Sonja Visentin, Giuseppe Ermondi, Emilia Turco, Giulia Caron and 1 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Andrea CostamagnaDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
Matteo Rossi SebastianoInstitut für Pharmacologie, Universität Bern, Inelspital INO-F, CH-3010, Bern, Switzerland.
Dora NataliniDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
Matilde SimoniDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
Giorgio ValabregaCandiolo Cancer Institute, FPO - IRCCS -, Candiolo, (TO), 10060, Italy.
Paola DefilippiDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
Sonja VisentinDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
Giuseppe ErmondiDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
Emilia TurcoDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
Giulia CaronDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
Sara CabodiDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy. sara.cabodi@unito.it.ORCID http://orcid.org/0000-0003-1248-6549

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Identifiers

PMID31758081
PMCPMC6874561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.